RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4

Marie K. Kirby, Ryne C. Ramaker, Jason Gertz, Nicholas S. Davis, Bobbi E. Johnston, Patsy G. Oliver, Katherine C. Sexton, Edward W. Greeno, John D. Christein, Martin J. Heslin, James A. Posey, William E. Grizzle, Selwyn M. Vickers, Donald J. Buchsbaum, Sara J. Cooper, Richard M. Myers

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background Pancreatic adenocarcinoma patients have low survival rates due to late-stage diagnosis and high rates of cancer recurrence even after surgical resection. It is important to understand the molecular characteristics associated with survival differences in pancreatic adenocarcinoma tumors that may inform patient care. Results RNA sequencing was performed for 51 patient tumor tissues extracted from patients undergoing surgical resection, and expression was associated with overall survival time from diagnosis. Our analysis uncovered 323 transcripts whose expression correlates with survival time in our pancreatic patient cohort. This genomic signature was validated in an independent RNA-seq dataset of 68 additional patients from the International Cancer Genome Consortium. We demonstrate that this transcriptional profile is largely independent of markers of cellular division and present a 19-transcript predictive model built from a subset of the 323 transcripts that can distinguish patients with differing survival times across both the training and validation patient cohorts. We present evidence that a subset of the survival-associated transcripts is associated with resistance to gemcitabine treatment in vitro, and reveal that reduced expression of one of the survival-associated transcripts, Angiopoietin-like 4, impairs growth of a gemcitabine-resistant pancreatic cancer cell line. Conclusions Gene expression patterns in pancreatic adenocarcinoma tumors can distinguish patients with differing survival outcomes after undergoing surgical resection, and the survival difference could be associated with the intrinsic gemcitabine sensitivity of primary patient tumors. Thus, these transcriptional differences may impact patient care by distinguishing patients who would benefit from a non-gemcitabine based therapy.

Original languageEnglish (US)
Pages (from-to)1169-1182
Number of pages14
JournalMolecular Oncology
Volume10
Issue number8
DOIs
StatePublished - Oct 1 2016

Fingerprint

RNA Sequence Analysis
Adenocarcinoma
gemcitabine
Survival
Neoplasms
Patient Care
Delayed Diagnosis
Pancreatic Neoplasms
Survival Rate
Genome
RNA

Keywords

  • ANGPTL4
  • Gemcitabine
  • Pancreatic adenocarcinoma
  • RNA-seq

Cite this

RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. / Kirby, Marie K.; Ramaker, Ryne C.; Gertz, Jason; Davis, Nicholas S.; Johnston, Bobbi E.; Oliver, Patsy G.; Sexton, Katherine C.; Greeno, Edward W.; Christein, John D.; Heslin, Martin J.; Posey, James A.; Grizzle, William E.; Vickers, Selwyn M.; Buchsbaum, Donald J.; Cooper, Sara J.; Myers, Richard M.

In: Molecular Oncology, Vol. 10, No. 8, 01.10.2016, p. 1169-1182.

Research output: Contribution to journalArticle

Kirby, MK, Ramaker, RC, Gertz, J, Davis, NS, Johnston, BE, Oliver, PG, Sexton, KC, Greeno, EW, Christein, JD, Heslin, MJ, Posey, JA, Grizzle, WE, Vickers, SM, Buchsbaum, DJ, Cooper, SJ & Myers, RM 2016, 'RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4', Molecular Oncology, vol. 10, no. 8, pp. 1169-1182. https://doi.org/10.1016/j.molonc.2016.05.004
Kirby, Marie K. ; Ramaker, Ryne C. ; Gertz, Jason ; Davis, Nicholas S. ; Johnston, Bobbi E. ; Oliver, Patsy G. ; Sexton, Katherine C. ; Greeno, Edward W. ; Christein, John D. ; Heslin, Martin J. ; Posey, James A. ; Grizzle, William E. ; Vickers, Selwyn M. ; Buchsbaum, Donald J. ; Cooper, Sara J. ; Myers, Richard M. / RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. In: Molecular Oncology. 2016 ; Vol. 10, No. 8. pp. 1169-1182.
@article{14e6e2d99ecb44be860e1bd8caa4fbdd,
title = "RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4",
abstract = "Background Pancreatic adenocarcinoma patients have low survival rates due to late-stage diagnosis and high rates of cancer recurrence even after surgical resection. It is important to understand the molecular characteristics associated with survival differences in pancreatic adenocarcinoma tumors that may inform patient care. Results RNA sequencing was performed for 51 patient tumor tissues extracted from patients undergoing surgical resection, and expression was associated with overall survival time from diagnosis. Our analysis uncovered 323 transcripts whose expression correlates with survival time in our pancreatic patient cohort. This genomic signature was validated in an independent RNA-seq dataset of 68 additional patients from the International Cancer Genome Consortium. We demonstrate that this transcriptional profile is largely independent of markers of cellular division and present a 19-transcript predictive model built from a subset of the 323 transcripts that can distinguish patients with differing survival times across both the training and validation patient cohorts. We present evidence that a subset of the survival-associated transcripts is associated with resistance to gemcitabine treatment in vitro, and reveal that reduced expression of one of the survival-associated transcripts, Angiopoietin-like 4, impairs growth of a gemcitabine-resistant pancreatic cancer cell line. Conclusions Gene expression patterns in pancreatic adenocarcinoma tumors can distinguish patients with differing survival outcomes after undergoing surgical resection, and the survival difference could be associated with the intrinsic gemcitabine sensitivity of primary patient tumors. Thus, these transcriptional differences may impact patient care by distinguishing patients who would benefit from a non-gemcitabine based therapy.",
keywords = "ANGPTL4, Gemcitabine, Pancreatic adenocarcinoma, RNA-seq",
author = "Kirby, {Marie K.} and Ramaker, {Ryne C.} and Jason Gertz and Davis, {Nicholas S.} and Johnston, {Bobbi E.} and Oliver, {Patsy G.} and Sexton, {Katherine C.} and Greeno, {Edward W.} and Christein, {John D.} and Heslin, {Martin J.} and Posey, {James A.} and Grizzle, {William E.} and Vickers, {Selwyn M.} and Buchsbaum, {Donald J.} and Cooper, {Sara J.} and Myers, {Richard M.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.molonc.2016.05.004",
language = "English (US)",
volume = "10",
pages = "1169--1182",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4

AU - Kirby, Marie K.

AU - Ramaker, Ryne C.

AU - Gertz, Jason

AU - Davis, Nicholas S.

AU - Johnston, Bobbi E.

AU - Oliver, Patsy G.

AU - Sexton, Katherine C.

AU - Greeno, Edward W.

AU - Christein, John D.

AU - Heslin, Martin J.

AU - Posey, James A.

AU - Grizzle, William E.

AU - Vickers, Selwyn M.

AU - Buchsbaum, Donald J.

AU - Cooper, Sara J.

AU - Myers, Richard M.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background Pancreatic adenocarcinoma patients have low survival rates due to late-stage diagnosis and high rates of cancer recurrence even after surgical resection. It is important to understand the molecular characteristics associated with survival differences in pancreatic adenocarcinoma tumors that may inform patient care. Results RNA sequencing was performed for 51 patient tumor tissues extracted from patients undergoing surgical resection, and expression was associated with overall survival time from diagnosis. Our analysis uncovered 323 transcripts whose expression correlates with survival time in our pancreatic patient cohort. This genomic signature was validated in an independent RNA-seq dataset of 68 additional patients from the International Cancer Genome Consortium. We demonstrate that this transcriptional profile is largely independent of markers of cellular division and present a 19-transcript predictive model built from a subset of the 323 transcripts that can distinguish patients with differing survival times across both the training and validation patient cohorts. We present evidence that a subset of the survival-associated transcripts is associated with resistance to gemcitabine treatment in vitro, and reveal that reduced expression of one of the survival-associated transcripts, Angiopoietin-like 4, impairs growth of a gemcitabine-resistant pancreatic cancer cell line. Conclusions Gene expression patterns in pancreatic adenocarcinoma tumors can distinguish patients with differing survival outcomes after undergoing surgical resection, and the survival difference could be associated with the intrinsic gemcitabine sensitivity of primary patient tumors. Thus, these transcriptional differences may impact patient care by distinguishing patients who would benefit from a non-gemcitabine based therapy.

AB - Background Pancreatic adenocarcinoma patients have low survival rates due to late-stage diagnosis and high rates of cancer recurrence even after surgical resection. It is important to understand the molecular characteristics associated with survival differences in pancreatic adenocarcinoma tumors that may inform patient care. Results RNA sequencing was performed for 51 patient tumor tissues extracted from patients undergoing surgical resection, and expression was associated with overall survival time from diagnosis. Our analysis uncovered 323 transcripts whose expression correlates with survival time in our pancreatic patient cohort. This genomic signature was validated in an independent RNA-seq dataset of 68 additional patients from the International Cancer Genome Consortium. We demonstrate that this transcriptional profile is largely independent of markers of cellular division and present a 19-transcript predictive model built from a subset of the 323 transcripts that can distinguish patients with differing survival times across both the training and validation patient cohorts. We present evidence that a subset of the survival-associated transcripts is associated with resistance to gemcitabine treatment in vitro, and reveal that reduced expression of one of the survival-associated transcripts, Angiopoietin-like 4, impairs growth of a gemcitabine-resistant pancreatic cancer cell line. Conclusions Gene expression patterns in pancreatic adenocarcinoma tumors can distinguish patients with differing survival outcomes after undergoing surgical resection, and the survival difference could be associated with the intrinsic gemcitabine sensitivity of primary patient tumors. Thus, these transcriptional differences may impact patient care by distinguishing patients who would benefit from a non-gemcitabine based therapy.

KW - ANGPTL4

KW - Gemcitabine

KW - Pancreatic adenocarcinoma

KW - RNA-seq

UR - http://www.scopus.com/inward/record.url?scp=84992740842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992740842&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2016.05.004

DO - 10.1016/j.molonc.2016.05.004

M3 - Article

C2 - 27282075

AN - SCOPUS:84992740842

VL - 10

SP - 1169

EP - 1182

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 8

ER -